A deterministic snapshot of the global clinical-trial landscape — every figure reproducible from the ClinicaLister knowledge graph.
Registered in the past 7 days.
Trials that moved to a new overall status.
Terminations, withdrawals and suspensions — with the sponsor's stated reason.
Sponsor stopped enrollment at 50 of 70 planned patients because an activity signal had been observed in lymphoma and further enrollment would not add significantly to interpretation of efficacy or safety.
Study closed after Stage 1 (15 of 40 planned patients treated) due to lack of treatment response; criteria to proceed to Stage 2 were not met.
Due to recruitment challenges during the trial, this study was terminated early by the Sponsor.
Sponsor stopped enrollment at 67 of about 100 planned participants after an unplanned interim analysis confirmed the primary PFS endpoint had been reached. Enrolled participants were followed to their PFS endpoint.
No dose-limiting toxicity was observed. The sponsor concluded the study after 3 subjects at the higher dose level; the optional 10-subject expansion cohort was not enrolled.
Sponsor business decision: enrollment closed after the Phase 1 dose escalation, before an MTD was reached. The Phase 2 portion was not conducted.
Primary endpoint (PFS) not met at the final analysis; sponsor decided to stop the study before the planned final overall survival analysis.
NOT ENOUGH PARTICIPANTS
Sponsor closed enrollment in April 2013 following a change in the palifosfamide development plan (business decision), not for safety reasons. Enrolled participants continued treatment and were followed for survival
Site did not proceed with this study
Did not meet recruitment goals
0 approvals month-to-date.
| Sponsor | Drug | Approved |
|---|---|---|
| BIONPHARMA INC | Unknown | 2026-09-29 |
| ZYDUS LIFESCIENCES | MUPIROCIN CALCIUM | 2026-09-29 |
| UPSHER SMITH LABS | PREDNISOLONE ACETATE | 2026-09-28 |
| NEPHRON | DEXMEDETOMIDINE HYDROCHLORIDE | 2026-09-28 |
| RARE THYROID THERAPEUTICS INTERNATIONAL AB | TIRATRICO | 2026-09-28 |
7.4% of the last year's EMA authorisations were conditional.
None authorised this period.
1 new · 0 resolved · 101 currently active.
| Newly reported shortage | Posted |
|---|---|
| Ivermectin Tablet | 2026-09-29 |
Most new trials this week.
Industry sponsors, new trials · trailing 28 days.
New links where the molecule is the studied intervention.
FDA device clearance data is current; MAUDE adverse-event and recall feeds lag ~1-2 months.
Whole-corpus totals and rankings, recomputed every week.
Monthly new registrations across ClinicalTrials.gov. Puts the weekly count in context.
By linked trials (MONDO rollup).
Among the 92,496 trials with a mapped site location — not the whole corpus.
| Sponsor | Trials |
|---|---|
| Assiut University | 4,981 |
| Cairo University | 4,874 |
| GlaxoSmithKline | 3,641 |
| Assistance Publique - Hôpitaux de Paris | 3,564 |
| National Cancer Institute (NCI) | 3,553 |
| AstraZeneca | 3,487 |
| Pfizer | 3,313 |
| Mayo Clinic | 3,256 |
| M.D. Anderson Cancer Center | 3,037 |
| Novartis Pharmaceuticals | 2,709 |
| National Taiwan University Hospital | 2,605 |
| Massachusetts General Hospital | 2,574 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 2,441 |
| Boehringer Ingelheim | 2,297 |
| Riphah International University | 2,171 |
| University of California, San Francisco | 2,165 |
| Stanford University | 2,157 |
| Merck Sharp & Dohme LLC | 2,152 |
| Hoffmann-La Roche | 2,095 |
| Eli Lilly and Company | 2,089 |
| Duke University | 2,057 |
| Memorial Sloan Kettering Cancer Center | 1,954 |
| Ain Shams University | 1,910 |
| Seoul National University Hospital | 1,895 |
| Hospices Civils de Lyon | 1,850 |
| Condition | Trials |
|---|---|
| breast cancer | 11,929 |
| obesity disorder | 9,748 |
| type 2 diabetes mellitus | 9,236 |
| chronic pain syndrome | 8,919 |
| cancer | 8,414 |
| HIV infectious disease | 8,267 |
| COVID-19 | 7,662 |
| non-small cell lung carcinoma | 6,478 |
| hypertensive disorder | 6,193 |
| diabetes mellitus | 6,183 |
| colorectal cancer | 6,101 |
| cerebrovascular disorder | 6,089 |
| coronary artery disorder | 6,016 |
| prostate cancer | 5,918 |
| depressive disorder | 5,906 |
| cardiovascular disorder | 5,663 |
| anxiety disorder | 5,022 |
| heart failure | 4,963 |
| injury | 4,555 |
| Parkinson disease | 4,499 |
| asthma | 4,459 |
| cognitive disorder | 4,249 |
| lung cancer | 4,102 |
| neuralgia | 3,911 |
| plasma cell myeloma | 3,695 |
| Molecule | Trials |
|---|---|
| carboplatin | 7,265 |
| paclitaxel | 5,650 |
| isoniazid | 5,383 |
| prednisolone | 5,362 |
| cyclophosphamide | 5,162 |
| ropivacaine | 4,978 |
| dexamethasone | 4,870 |
| bevacizumab | 4,700 |
| cisplatin | 4,546 |
| lidocaine | 3,701 |
| aspirin | 3,451 |
| gemcitabine | 3,244 |
| bupivacaine | 3,221 |
| pembrolizumab | 3,038 |
| metformin | 3,023 |
| desoxycorticosterone acetate | 2,994 |
| sitagliptin and metformin hydrochloride | 2,979 |
| rituximab | 2,968 |
| meprednisone | 2,850 |
| sitagliptin metformin hydrochloride | 2,791 |
| docetaxel | 2,789 |
| dapagliflozin metformin hydrochloride | 2,788 |
| linagliptin and metformin hydrochloride | 2,778 |
| fluorouracil | 2,771 |
| alogliptin and metformin hydrochloride | 2,720 |
Standing competitive & regulatory landscape — who is developing what, at which stage, and which drugs are about to lose exclusivity.
Active trials by the most prolific industry sponsors, split by phase.
| Phase 1 | Phase 2 | Phase 3 | |
|---|---|---|---|
| GlaxoSmithKline | 1,096 | 863 | 901 |
| AstraZeneca | 1,023 | 552 | 811 |
| Pfizer | 1,178 | 710 | 669 |
| Novartis Pharmaceuticals | 513 | 841 | 739 |
| Boehringer Ingelheim | 1,077 | 322 | 403 |
| Merck Sharp & Dohme LLC | 704 | 553 | 744 |
| Hoffmann-La Roche | 495 | 483 | 577 |
| Eli Lilly and Company | 837 | 536 | 551 |
FDA drugs whose exclusivity expires soon (distinct substances).
| Drug (losing exclusivity < 6mo) | Expires |
|---|---|
| Afamelanotide | 2026-10-08 |
| Binimetinib | 2026-10-11 |
| Tenapanor Hydrochloride | 2026-10-17 |
| Pilocarpine Hydrochloride | 2026-10-17 |
| Acetaminophen; Ibuprofen Sodium | 2026-10-17 |
| Treprostinil Diolamine | 2026-10-18 |
| Edoxaban Tosylate | 2026-10-18 |
| Adapalene; Benzoyl Peroxide; Clindamycin Phosphate | 2026-10-20 |
| Ivabradine | 2026-10-22 |
| Bupivacaine | 2026-11-09 |
| Fluticasone Furoate; Vilanterol Trifenatate | 2026-11-13 |
| Enzalutamide | 2026-11-17 |
| Givosiran Sodium | 2026-11-20 |
| Dasatinib | 2026-12-05 |
| Golodirsen | 2026-12-12 |
FDA drugs carrying each designation.
Molecules most often used as the comparator arm (the standard to beat).
Every figure is a deterministic SQL aggregate over the ClinicaLister knowledge graph as of the report date. No figure is AI-generated or estimated; each is reproducible and traceable to its public source.
Sources: ClinicalTrials.gov · EU CTIS · openFDA (drugs, devices, shortages) · EMA · MONDO disease ontology · GSRS · GUDID · Europe PMC / PubMed
Every figure above is a deterministic aggregate over the ClinicaLister knowledge graph — and one click deep in the product, with a source behind each claim.
Machine-readable: download this edition as JSON above, or query the full archive programmatically via the public get_public_report_snapshots endpoint.